Microbix Biosystems Inc. (MBX) - Net Assets
Based on the latest financial reports, Microbix Biosystems Inc. (MBX) has net assets worth CA$27.79 Million CAD (≈ $20.10 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$37.41 Million ≈ $27.06 Million USD) and total liabilities (CA$9.62 Million ≈ $6.96 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Microbix Biosystems Inc. (MBX) financial obligations for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$27.79 Million |
| % of Total Assets | 74.28% |
| Annual Growth Rate | 4.55% |
| 5-Year Change | 49.75% |
| 10-Year Change | 81.72% |
| Growth Volatility | 61.06 |
Microbix Biosystems Inc. - Net Assets Trend (1997–2025)
This chart illustrates how Microbix Biosystems Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore how large is Microbix Biosystems Inc.'s balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Microbix Biosystems Inc. (1997–2025)
The table below shows the annual net assets of Microbix Biosystems Inc. from 1997 to 2025. For live valuation and market cap data, see MBX stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | CA$27.79 Million ≈ $20.10 Million |
-1.80% |
| 2024-09-30 | CA$28.30 Million ≈ $20.47 Million |
+14.92% |
| 2023-09-30 | CA$24.62 Million ≈ $17.81 Million |
-1.26% |
| 2022-09-30 | CA$24.94 Million ≈ $18.04 Million |
+34.40% |
| 2021-09-30 | CA$18.56 Million ≈ $13.42 Million |
+180.33% |
| 2020-09-30 | CA$6.62 Million ≈ $4.79 Million |
-37.18% |
| 2019-09-30 | CA$10.54 Million ≈ $7.62 Million |
+1.78% |
| 2018-09-30 | CA$10.35 Million ≈ $7.49 Million |
-31.77% |
| 2017-09-30 | CA$15.17 Million ≈ $10.98 Million |
-0.77% |
| 2016-09-30 | CA$15.29 Million ≈ $11.06 Million |
+11.81% |
| 2015-09-30 | CA$13.68 Million ≈ $9.89 Million |
+38.96% |
| 2014-09-30 | CA$9.84 Million ≈ $7.12 Million |
+72.02% |
| 2013-09-30 | CA$5.72 Million ≈ $4.14 Million |
+38.74% |
| 2012-09-30 | CA$4.12 Million ≈ $2.98 Million |
-19.89% |
| 2011-09-30 | CA$5.15 Million ≈ $3.72 Million |
-8.84% |
| 2010-09-30 | CA$5.65 Million ≈ $4.09 Million |
-11.93% |
| 2009-09-30 | CA$6.41 Million ≈ $4.64 Million |
-15.86% |
| 2008-09-30 | CA$7.62 Million ≈ $5.51 Million |
+233.83% |
| 2007-09-30 | CA$2.28 Million ≈ $1.65 Million |
+54.41% |
| 2006-09-30 | CA$1.48 Million ≈ $1.07 Million |
-46.59% |
| 2005-09-30 | CA$2.77 Million ≈ $2.00 Million |
+21.21% |
| 2004-09-30 | CA$2.28 Million ≈ $1.65 Million |
+14.89% |
| 2003-09-30 | CA$1.99 Million ≈ $1.44 Million |
-6.17% |
| 2002-09-30 | CA$2.12 Million ≈ $1.53 Million |
+3.39% |
| 2001-09-30 | CA$2.05 Million ≈ $1.48 Million |
+16.19% |
| 2000-09-30 | CA$1.76 Million ≈ $1.28 Million |
+3.72% |
| 1999-09-30 | CA$1.70 Million ≈ $1.23 Million |
-73.44% |
| 1998-09-30 | CA$6.40 Million ≈ $4.63 Million |
-20.00% |
| 1997-09-30 | CA$8.00 Million ≈ $5.79 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Microbix Biosystems Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9009.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CA$50.43 Million | 181.49% |
| Other Comprehensive Income | CA$2.27 Million | 8.18% |
| Other Components | CA$10.72 Million | 38.58% |
| Total Equity | CA$27.79 Million | 100.00% |
Microbix Biosystems Inc. Competitors by Market Cap
The table below lists competitors of Microbix Biosystems Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ovaro Kiinteistosijoitus Oyj
HE:OVARO
|
$25.62 Million |
|
Pamapol S.A.
WAR:PMP
|
$25.63 Million |
|
Boundless Bio, Inc. Common Stock
NASDAQ:BOLD
|
$25.63 Million |
|
Shinpoong Pharmaceutical Co Ltd
KO:019175
|
$25.64 Million |
|
Zenith Minerals Ltd
AU:ZNC
|
$25.60 Million |
|
Adore Beauty Group Ltd
AU:ABY
|
$25.60 Million |
|
System1 Inc
NYSE:SST
|
$25.59 Million |
|
Eurotel SA
WAR:ETL
|
$25.58 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Microbix Biosystems Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 28,297,428 to 27,787,542, a change of -509,886 (-1.8%).
- Net loss of 2,245,812 reduced equity.
- Share repurchases of 1,730,586 reduced equity.
- Other factors increased equity by 3,466,512.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-2.25 Million | -8.08% |
| Share Repurchases | CA$1.73 Million | -6.23% |
| Other Changes | CA$3.47 Million | +12.48% |
| Total Change | CA$- | -1.80% |
Book Value vs Market Value Analysis
This analysis compares Microbix Biosystems Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.28x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.03x to 1.28x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1997-09-30 | CA$0.25 | CA$0.26 | x |
| 1998-09-30 | CA$0.18 | CA$0.26 | x |
| 1999-09-30 | CA$0.05 | CA$0.26 | x |
| 2000-09-30 | CA$0.05 | CA$0.26 | x |
| 2001-09-30 | CA$0.06 | CA$0.26 | x |
| 2002-09-30 | CA$0.06 | CA$0.26 | x |
| 2003-09-30 | CA$0.05 | CA$0.26 | x |
| 2004-09-30 | CA$0.07 | CA$0.26 | x |
| 2005-09-30 | CA$0.08 | CA$0.26 | x |
| 2006-09-30 | CA$0.04 | CA$0.26 | x |
| 2007-09-30 | CA$0.06 | CA$0.26 | x |
| 2008-09-30 | CA$0.17 | CA$0.26 | x |
| 2009-09-30 | CA$0.14 | CA$0.26 | x |
| 2010-09-30 | CA$0.12 | CA$0.26 | x |
| 2011-09-30 | CA$0.09 | CA$0.26 | x |
| 2012-09-30 | CA$0.07 | CA$0.26 | x |
| 2013-09-30 | CA$0.09 | CA$0.26 | x |
| 2014-09-30 | CA$0.14 | CA$0.26 | x |
| 2015-09-30 | CA$0.17 | CA$0.26 | x |
| 2016-09-30 | CA$0.18 | CA$0.26 | x |
| 2017-09-30 | CA$0.18 | CA$0.26 | x |
| 2018-09-30 | CA$0.11 | CA$0.26 | x |
| 2019-09-30 | CA$0.11 | CA$0.26 | x |
| 2020-09-30 | CA$0.06 | CA$0.26 | x |
| 2021-09-30 | CA$0.13 | CA$0.26 | x |
| 2022-09-30 | CA$0.18 | CA$0.26 | x |
| 2023-09-30 | CA$0.18 | CA$0.26 | x |
| 2024-09-30 | CA$0.21 | CA$0.26 | x |
| 2025-09-30 | CA$0.20 | CA$0.26 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Microbix Biosystems Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -8.08%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -12.08%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 1.35x
- Recent ROE (-8.08%) is above the historical average (-34.89%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1997 | -1.25% | -3.70% | 0.30x | 1.14x | CA$-900.00K |
| 1998 | -32.81% | -67.74% | 0.37x | 1.31x | CA$-2.74 Million |
| 1999 | -276.47% | -293.75% | 0.59x | 1.59x | CA$-4.87 Million |
| 2000 | -25.53% | -24.25% | 0.64x | 1.65x | CA$-626.55K |
| 2001 | 11.77% | 8.07% | 1.01x | 1.44x | CA$36.24K |
| 2002 | 3.28% | 2.48% | 1.03x | 1.28x | CA$-142.32K |
| 2003 | -18.30% | -12.78% | 0.96x | 1.50x | CA$-562.47K |
| 2004 | 0.62% | 0.35% | 1.21x | 1.48x | CA$-214.09K |
| 2005 | 4.53% | 2.87% | 1.11x | 1.43x | CA$-151.27K |
| 2006 | -141.50% | -57.41% | 0.92x | 2.68x | CA$-2.24 Million |
| 2007 | -118.79% | -66.98% | 0.70x | 2.54x | CA$-2.94 Million |
| 2008 | -48.13% | -73.45% | 0.34x | 1.92x | CA$-4.43 Million |
| 2009 | -38.75% | -40.85% | 0.43x | 2.20x | CA$-3.13 Million |
| 2010 | -44.95% | -39.28% | 0.45x | 2.53x | CA$-3.10 Million |
| 2011 | -50.77% | -41.97% | 0.45x | 2.68x | CA$-3.13 Million |
| 2012 | -63.94% | -39.53% | 0.49x | 3.28x | CA$-3.05 Million |
| 2013 | 0.02% | 0.02% | 0.60x | 2.22x | CA$-570.76K |
| 2014 | 1.72% | 2.01% | 0.47x | 1.83x | CA$-815.22K |
| 2015 | 4.49% | 6.92% | 0.38x | 1.72x | CA$-753.71K |
| 2016 | 4.89% | 7.86% | 0.38x | 1.65x | CA$-780.77K |
| 2017 | -24.91% | -37.11% | 0.39x | 1.74x | CA$-5.30 Million |
| 2018 | -83.27% | -68.91% | 0.65x | 1.87x | CA$-9.66 Million |
| 2019 | 0.30% | 0.24% | 0.68x | 1.86x | CA$-1.02 Million |
| 2020 | -94.08% | -59.17% | 0.67x | 2.36x | CA$-6.89 Million |
| 2021 | 8.79% | 8.77% | 0.64x | 1.55x | CA$-225.43K |
| 2022 | 7.17% | 9.38% | 0.58x | 1.33x | CA$-705.18K |
| 2023 | -0.16% | -0.24% | 0.46x | 1.45x | CA$-2.50 Million |
| 2024 | 12.44% | 13.86% | 0.67x | 1.35x | CA$690.44K |
| 2025 | -8.08% | -12.08% | 0.50x | 1.35x | CA$-5.02 Million |
Industry Comparison
This section compares Microbix Biosystems Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $24,209,535
- Average return on equity (ROE) among peers: -379.23%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Microbix Biosystems Inc. (MBX) | CA$27.79 Million | -1.25% | 0.35x | $25.60 Million |
| Appili Therapeutics Inc (APLI) | $-13.40 Million | 0.00% | 0.00x | $1.86 Million |
| Aptose Biosciences Inc (APS) | $7.33 Million | -189.11% | 0.18x | $4.36 Million |
| Arch Biopartners Inc (ARCH) | $1.06 Million | -79.15% | 0.19x | $20.88 Million |
| Biomind Labs Inc (BMND) | $-1.30 Million | 0.00% | 0.00x | $6.98 Million |
| Cybin Inc (CYBN) | $237.20 Million | -47.70% | 0.09x | $301.37 Million |
| Eupraxia Pharmaceuticals Inc (EPRX) | $1.18 Million | -3177.89% | 21.71x | $393.86 Million |
| Devonian Health Group Inc (GSD) | $14.25 Million | -32.28% | 0.35x | $20.01 Million |
| Helix BioPharma Corp. (HBP) | $-1.39 Million | 0.00% | 0.00x | $116.58 Million |
| Hemostemix Inc (HEM) | $-6.77 Million | 0.00% | 0.00x | $8.18 Million |
| Universal Ibogaine Inc (IBO) | $3.94 Million | -266.20% | 0.60x | $1.13 Million |
About Microbix Biosystems Inc.
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures a wide range of critical biological materials and medical devices for the global diagnostics industry, notably test ingredients (Antigen business) used in immunoassays… Read more